{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:54Z","timestamp":1756425774195,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,2,6]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>A 56-year-old man undergoing immunotherapy treatment for metastatic melanoma presented with sudden onset testicular pain radiating into his abdomen. On examination, the abdomen was generally tender with associated guarding. Imaging revealed a perforation of the small bowel at the site of a metastatic lesion. Histology revealed that this process was non-inflammatory in nature. A diagnosis of small bowel perforation secondary to immunotherapy driven rapid tumour regression was made. The patient was treated with a small bowel resection plus anastomosis and made a full recovery. This case highlights the rare potential side effect of immunotherapy in causing non-inflammatory bowel perforations secondary to rapid tumour regression.<\/jats:p>","DOI":"10.1136\/bcr-2019-232304","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T04:29:25Z","timestamp":1582259365000},"page":"e232304","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Case of small bowel perforation secondary to nivolumab and ipilimumab related tumour regression"],"prefix":"10.1136","volume":"13","author":[{"given":"Kishen Rajan","family":"Patel","sequence":"first","affiliation":[{"name":"Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennard YW","family":"Lee","sequence":"additional","affiliation":[{"name":"Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Tripathy","sequence":"additional","affiliation":[{"name":"Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McKean","sequence":"additional","affiliation":[{"name":"Radiology, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2025082800425841000_13.2.e232304.1","unstructured":"Melanoma skin cancer statistics [Internet]. Cancer Research UK, 2015. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/melanoma-skin-cancer [Accessed 16 Jul 2019]."},{"key":"2025082800425841000_13.2.e232304.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3463"},{"key":"2025082800425841000_13.2.e232304.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"2025082800425841000_13.2.e232304.4","unstructured":"Overview | Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | Guidance | NICE [Internet]. Available: https:\/\/www.nice.org.uk\/guidance\/ta268 [Accessed 16 Jul 2019]."},{"key":"2025082800425841000_13.2.e232304.5","unstructured":"Overview | Nivolumab for treating advanced (unresectable or metastatic) melanoma | Guidance | NICE [Internet].. Available: https:\/\/www.nice.org.uk\/guidance\/ta384 [Accessed 16 Jul 2019]."},{"key":"2025082800425841000_13.2.e232304.6","unstructured":"BNF: British National Formulary - NICE [Internet]. Available: https:\/\/bnf.nice.org.uk\/drug\/ipilimumab.html [Accessed 16 Jul 2019]."},{"key":"2025082800425841000_13.2.e232304.7","unstructured":"BNF: British National Formulary - NICE [Internet]. Available: https:\/\/bnf.nice.org.uk\/drug\/nivolumab.html [Accessed 16 Jul 2019]."},{"key":"2025082800425841000_13.2.e232304.8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00000658-198211000-00011","article-title":"Free perforation of the small intestine","volume":"196","author":"Rajagopalan","year":"1982","journal-title":"Ann Surg"},{"key":"2025082800425841000_13.2.e232304.9","doi-asserted-by":"crossref","unstructured":"Li W , Zhou Y , Li Q , et al . Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner\u2019s syndrome: report of two cases. World J Surg Oncol 2016;14.doi:10.1186\/s12957-016-0935-0","DOI":"10.1186\/s12957-016-0935-0"},{"key":"2025082800425841000_13.2.e232304.10","first-page":"e1182","article-title":"Ipilimumab as a cause of severe Pan-Colitis and colonic perforation","volume":"9","author":"Shah","year":"2017","journal-title":"Cureus"},{"key":"2025082800425841000_13.2.e232304.11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40792-017-0370-7","article-title":"Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report","volume":"3","author":"Yasuda","year":"2017","journal-title":"Surg Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232304","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:43:11Z","timestamp":1756366991000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,20]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/bcr-2019-232304"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232304","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}